Share

cover art for Addressing Barriers in Gene Therapy

GEN Podcasts

Addressing Barriers in Gene Therapy

•

In this podcast episode, join us as we delve into addressing regulatory challenges in gene therapy with María Orío, the Head of Regulatory Affairs at Viralgen. Learn about the mission of Viralgen as a Contract Development and Manufacturing Organization specializing in Adeno-Associated Virus (AAV) gene therapy products. Uncover the unique challenges faced by the gene therapy industry, from the evolving regulatory landscape to the setting of acceptance criteria with limited available data. Learn how Viralgen addresses these challenges, leveraging historical data and innovative approaches. Gain valuable insights from the Chemistry, Manufacturing, and Controls (CMC) perspective, while learning how regulatory agencies are actively supporting sponsors in their quest for life-changing treatments.

More episodes

View all episodes

  • 3. Toward Connected Laboratory Ecosystems

    25:52||Ep. 3
    These days, many laboratories are eager to apply AI, but the systems and workflows that they have implemented often stand in the way. When systems run separately, information gets trapped in silos and scientific context is lost between steps. Also, manual handoffs slow the work down and introduce risk at various points in lab processes. Connecting those systems and workflows first gives AI the operational and scientific context it needs to deliver value that can be both trusted and scaled.In this GEN podcast, the third in a series, LabVantage’s Denise Bell discusses how laboratories can reduce operational fragmentation and build connected, scalable operations. The discussion covers workflow orchestration across laboratory functions, ways to reduce manual handoffs and information silos, and offers some practical starting points for AI adoption. It also looks at how bringing LIMS, ELN, LES, and SDMS together in a unified laboratory execution environment enables workflow intelligence and AI assistance in the right scientific and operational context.Speaker: Denise BellModerator: Uduak Thomas
  • 1. Precision Automation Meets Biology

    41:53||Ep. 1
    Episode 1: Precision Automation Meets Biology Central question: How can automation help scientists move faster without losing sight of the biology? This opening episode would introduce precision automation as the connective tissue across the Molecular Devices portfolio. Rather than defining automation simply as higher throughput, we would explore how purpose-built tools help biologists reduce repetitive work, control variability, improve consistency, and focus more of their time on scientific decisions. Potential discussion points: What “precision automation” means for a working biologist Why automation should adapt to the science — not force the science into a rigid process Where manual variability enters cell-based research The balance between speed, consistency, flexibility, and scientific control How purpose-built instruments, software, and expertise work together Why researchers may need different solutions at different points in their journeySpeaker: Matt Stoltz Moderator: Uduak Thomas
  • 2. Data Integrity as the Foundation for AI

    17:54||Ep. 2
    Artificial intelligence is advancing quickly into laboratory operations, which is why thinking about the quality and integrity of the supporting data early on is important. In regulated environments, that means understanding where the data came from, how it changes, and how AI-generated insights or recommendations can be traced, reviewed, trusted, and ultimately defended.In this GEN podcast, LabVantage’s Gary Stimson digs into what it takes to build a data foundation for trustworthy AI. The discussion covers concepts like data lineage, traceability, explainability and governance, and the importance of audit-ready laboratory operations. It also looks at the role of intended use, ongoing monitoring, and human review in deploying AI responsibly.
  • 2. Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and Sustainability

    33:40||Ep. 2
    Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.In this GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.Guest SpeakersSteve Barr, PhD -- Head of Small Molecule Business Unit and VP Global Alliances, SK Pharmteco.Darryl Ratty -- Executive Director of Global ESG (Environmental, Social and Governance), SK Pharmteco.Bill Dubay -- VP, Global Research and Development, SK Pharmteco.Moderator:Kevin Davies, PhD, Editorial Director, GEN
  • 1. Beyond the Technology: AI Readiness in Regulated Laboratories

    24:18||Ep. 1
    This episode establishes the broader context for AI adoption. Rather than focusing on AI tools themselves, the discussion explores what laboratories must have in place before AI can be applied responsibly. Key discussion areas include: Why fragmented workflows and disconnected systems limit AI effectiveness The importance of trusted, connected laboratory data Human-guided AI and human-in-the-loop governance Why compliance and auditability should be built into AI-enabled workflows from the outset Relevant reference to LabVantage CORTEX: LabVantage CORTEX embeds AI within laboratory execution workflows so that intelligence operates within existing scientific and compliance processes, rather than as an external layer.
  • 1. Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness.

    35:27||Ep. 1
    Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a number of manufacturing challenges, including higher doses, tighter control of impurities, greater batch consistency, and scalable processes to meet both clinical and commercial needs.In this GEN Podcast, two experts from SK Pharmteco, a global CMO, address these challenges and lay out some best practices that guide the manufacture of lentiviral vectors with the requisite purity, robustness, and economic feasibility required for widespread clinical adoption.Guest speakers:Mardhani Aparajithan, Director of Manufacturing, Science and Technology, SK PharmtecoTatiana Nanda, PhD, CTO, Cell and Gene Therapy, SK PharmtecoModerator:Kevin Davies, PhD, Editorial Director, GEN
  • The Future of Bioinformatics: Scaling Interactive and Computational Workflows with Seqera

    18:01|
    Sponsored by SeqeraAs data volumes in life sciences continue to grow, bioinformaticians and researchers are more dependent than ever on solutions that help them streamline workflows, manage data, and scale their research. In this timely podcast, Evan Floden, CEO and co-founder of Seqera, shares how his company is addressing these needs through Nextflow—the open-source orchestrator for scalable, reproducible, and portable scientific workflows—and Seqera Platform, a unified solution for the entire scientific data lifecycle. He also discusses how Seqera has become a widely adopted solution, trusted by 13 of the top 20 pharmaceutical companies, empowering breakthroughs in drug discovery, genomics, clinical research, and.beyond.
  • Smart Vector Design for Improved Cell and Gene Therapies

    01:00:36|
    In the episode, we’re talking about vector design and delivery for gene therapies. The field of cell and gene therapies is advancing, but there are still challenges with delivery vectors that need to be addressed. In this podcast, experts discuss current immunogenicity hurdles, evolving DMPK strategies, and a new generation of bioanalytical tools that are contributing to the progress in the field.
  • From Functional Genomics to Cell Therapy: The Role of CRISPR-based Gene Editing

    58:33|
    There are an estimated 6,000 Mendelian diseases, most of which still lack cures. Gene editing is an essential technology for studies aimed at generating data about disease-causing gene mutations and networks in order to identify optimal therapeutic targets. In this episode, experts will discuss applications of gene editing to improve scientists understanding of the relationship between variant and disease in functional genomics studies. They will also talk about the Dharmacon product suite which is designed for CRISPR-based targeted editing in a wide range of cells.